Fidaxomicin
98%
- Product Code: 103578
CAS:
873857-62-6
| Molecular Weight: | 1058.04 g./mol | Molecular Formula: | C₅₂H₇₄Cl₂O₁₈ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | room temperature, dry |
Product Description:
Fidaxomicin is primarily used as an antibiotic to treat infections caused by Clostridium difficile, a bacterium that can lead to severe diarrhea and colitis. It is particularly effective in cases where the infection recurs after initial treatment with other antibiotics. The drug works by inhibiting RNA synthesis in the bacteria, thereby stopping their growth and spread. Fidaxomicin is favored in clinical settings due to its targeted action, which minimizes disruption to the normal gut flora compared to broader-spectrum antibiotics. This selective activity helps reduce the risk of secondary infections and promotes faster recovery in patients. It is typically administered orally, making it convenient for outpatient treatment.
Product Specification:
| Test | Specification |
|---|---|
| Appearance | White To Off-White Powder |
| Purity (%) | 97.5-100 |
| Carbon By Elemental Analysis | 57.9-59.5 |
| Infrared Spectrum | Conforms To Structure |
| Oxygen By Elemental Analysis | 26.4-27.7 |
| NMR | Consistent With Structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.050 | 10-20 days | €97.09 |
+
-
|
| 0.100 | 10-20 days | €174.65 |
+
-
|
| 0.250 | 10-20 days | €352.99 |
+
-
|
Fidaxomicin
Fidaxomicin is primarily used as an antibiotic to treat infections caused by Clostridium difficile, a bacterium that can lead to severe diarrhea and colitis. It is particularly effective in cases where the infection recurs after initial treatment with other antibiotics. The drug works by inhibiting RNA synthesis in the bacteria, thereby stopping their growth and spread. Fidaxomicin is favored in clinical settings due to its targeted action, which minimizes disruption to the normal gut flora compared to broader-spectrum antibiotics. This selective activity helps reduce the risk of secondary infections and promotes faster recovery in patients. It is typically administered orally, making it convenient for outpatient treatment.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
€0.00
€0.00
Total :